- ELISA tests, which detect and quantify substances such as proteins, hormones, and antibodies, are essential tools in diagnostics and biomedical research due to their high sensitivity, specificity, and adaptability across various disease areas, including infectious diseases, cancer, and autoimmune disorders
- The rising demand for ELISA tests is primarily driven by the global surge in chronic and infectious diseases, increasing emphasis on early disease detection, and expanding applications in drug development and therapeutic monitoring
- North America dominated the enzyme-linked immunosorbent assay (ELISA) tests market with the largest revenue share of 40.1% in 2024, supported by robust healthcare infrastructure, widespread use in clinical laboratories, and active R&D initiatives by pharmaceutical and biotech companies, particularly in the U.S., where extensive diagnostic testing and precision medicine are key drivers
- Asia-Pacific is expected to be the fastest growing region in the enzyme-linked immunosorbent assay (ELISA) tests market during the forecast period, fueled by expanding healthcare access, increasing government investments in diagnostics, and a rising burden of infectious diseases across emerging economies
- The sandwich ELISA segment dominated the enzyme-linked immunosorbent assay (ELISA) tests market with a share of 41.7% in 2024, attributed to its superior sensitivity and specificity in detecting low-abundance biomarkers, making it the preferred format in clinical diagnostics and biomedical research.
